Description: Chimerix, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of oral antiviral therapeutics for various medical needs. Its lead product includes CMX001, an orally administered drug that has completed Phase II clinical trials for the prevention of cytomegalovirus infection in hematopoietic stem cell transplant recipients; and is in Phase II clinical trials for treating double-stranded DNA viruses comprising herpesviruses, adenoviruses, BK viruses, papillomaviruses, and orthopoxviruses, as well as for the treatment of smallpox. The company also develops CMX157, an oral nucleotide compound that is in Phase I clinical trials to treat HIV infections. It has a collaboration and license agreement with Merck, Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Home Page: www.chimerix.com
CMRX Technical Analysis
2505 Meridian Parkway
Durham,
NC
27713
United States
Phone:
919 806 1074
Officers
| Name | Title |
|---|---|
| Mr. Michael A. Sherman M.B.A. | CEO, Pres & Director |
| Mr. Michael T. Andriole M.B.A. | Chief Bus. Officer, Sec. & CFO |
| Dr. Allen S. Melemed M.B.A., M.D. | Chief Medical Officer |
| Mr. David Jakeman CPA | Exec. Director of Fin. & Accounting and Principal Accounting Officer |
| Dr. Roy W. Ware | Chief Manufacturing & Technology Officer |
| Dr. Randall Lanier | Chief Science Officer |
| Ms. Michelle LaSpaluto | VP of Strategic Planning & Investor Relations |
| Dr. Michael A. Alrutz | Sr. VP, Gen. Counsel & Corp. Sec. |
| Dr. Joshua E. Allen | Chief Technology Officer of Imipridones |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 1.2136 |
|---|---|
| Trailing PE: | 1.1053 |
| Price-to-Book MRQ: | 0.6267 |
| Price-to-Sales TTM: | 5.2738 |
| IPO Date: | 2013-04-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 87 |